OCULAR THERAPEUTIX, INC
OCUL · Nasdaq · United States
Share price · OCUL
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when OCUL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 19 Oct 2026-8.4%
- Day beforeDirector or principal officer change
- 28 Sep 2026-20.7%
Nothing announced by OCUL that day or the session before.
- 10 Sep 2026-7.4%
Nothing announced by OCUL that day or the session before.
- 8 Sep 2026+6.9%
Nothing announced by OCUL that day or the session before.
- 11 Aug 2026+5.6%
Nothing announced by OCUL that day or the session before.
- 16 Jul 2026-8.0%
Nothing announced by OCUL that day or the session before.
- 2 Mar 2026+22.8%
- Day beforeRegulation FD disclosure
- 20 Feb 2026+10.7%
Nothing announced by OCUL that day or the session before.
- 17 Feb 2026-21.3%
- 8 Dec 2025+28.1%
- Day beforeOther material event
Share of unusual movement by asset
For each asset, the share of OCUL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Axitinib intravitreal implant (OTX-TKI)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 7% |
| Other company news (earnings, financing, releases naming no asset) | — | 35% |
| Sessions with no dated event | — | 58% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Glucocorticoid receptorSmall molecule | Allergic ConjunctivitisOcular Inflammation Ocular Inflammation and Pain | |
| Phase 3 | VEGF receptors + PDGF receptorsSmall molecule | Age-Related Macular Degeneration Wet Age-Related Macular Degeneration |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $13M | $75M | $532M | $95M-$66M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $13M | $54M | $600M | $79M-$67M operating cash flow | report ↗ |
| 2026-Q1 | $11M | $66M | $668M | $89M-$66M operating cash flow | report ↗ |
| 2025-Q3 | $15M | $52M | $346M | $69M-$51M operating cash flow | report ↗ |
| 2025-Q2 | $13M | $51M | $393M | $68M-$55M operating cash flow | report ↗ |
| 2025-Q1 | $11M | $43M | $351M | $64M-$45M operating cash flow | report ↗ |
| 2024-Q3 | $15M | $37M | $429M | $36M-$37M operating cash flow | report ↗ |
| 2024-Q2 | $16M | $29M | $461M | $44M-$25M operating cash flow | report ↗ |
| 2024-Q1 | $15M | $21M | $485M | $65M-$34M operating cash flow | report ↗ |
| 2023-Q3 | $15M | $15M | $112M | $0.5M-$7.7M operating cash flow | report ↗ |
| 2023-Q2 | $15M | $15M | $68M | $21M-$20M operating cash flow | report ↗ |
| 2023-Q1 | $13M | $15M | $81M | $30M-$20M operating cash flow | report ↗ |
| 2022-Q3 | $12M | $14M | $123M | $24M-$13M operating cash flow | report ↗ |
| 2022-Q2 | $12M | $13M | $136M | $19M-$11M operating cash flow | report ↗ |
| 2022-Q1 | $13M | $13M | $147M | $13M-$19M operating cash flow | report ↗ |
| 2021-Q3 | $12M | $13M | $181M | —-$13M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $52M | $197M | $739M | $66M-$205M operating cash flow | report ↗ |
Ocular Therapeutix reported full-year 2025 revenue of $51.95M, down 18.5% YoY, with R&D spend of $197.1M, up 54.4% YoY. Cash and equivalents were $738.67M, and the company reported a net loss of $265.94M.
The company said SOL-1 Phase 3 superiority data remain masked and are expected to be presented at the 49th Macula Society Annual Meeting; pending positive results, it plans to submit an NDA for AXPAXLI in wet AMD based on 52-week data. SOL-R completed randomization of 631 subjects in December 2025, with topline data accelerated to 1Q 2027; HELIOS-3 is underway, and SOL-X initiation is expected in 2Q 2026. Management guided that current cash supports operations into 2028, after raising approximately $475M gross (about $445.6M net) in a September 2025 equity offering.
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($461K), 29 sales ($3.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-06 | Sherif Riad · director | Award / grant | 28,000 | — | — | Form 4 |
| 2026-11-06 | Sherif Riad · director | Award / grant (derivative) | 88,000 | — | — | Form 4 |
| 2026-11-05 | Saroj Namrata · Chief Business Officer | Open-market sale | 35,370 | $6.55 | $232K | Form 4 |
| 2026-10-08 | Anderman Todd · Chief Legal Officer | Open-market sale | 11,984 | $7.29 | $87K | Form 4 |
| 2026-10-02 | Heier Jeffrey S. · Chief Scientific Officer | Open-market sale | 10,869 | $7.05 | $77K | Form 4 |
| 2026-10-02 | Kaiser Peter · Chief Development Officer | Open-market sale | 9,990 | $7.05 | $70K | Form 4 |
| 2026-08-31 | Notman Donald · Chief Operating Officer | Open-market sale | 1,099 | $10.24 | $11K | Form 4 |
| 2026-08-25 | Dugel Pravin · director, See Remarks | Gift | 50,092 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 266 reporting institutions held 206.6M shares ($1.7B, 93.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 32,653,764 | $276.6M |
| 2 | Deep Track Capital, LP | 19,686,282 | $166.7M |
| 3 | BlackRock, Inc. | 16,132,931 | $136.6M |
| 4 | Avoro Capital Advisors LLC | 12,315,000 | $104.3M |
| 5 | Summer Road LLC | 11,879,825 | $100.6M |
| 6 | Venrock Adviser, LLC | 10,346,926 | $87.6M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 8,719,039 | $73.9M |
| 8 | ALLIANCEBERNSTEIN L.P. | 4,129,687 | $50.1M |
| 9 | Point72 Asset Management, L.P. | 5,534,985 | $46.9M |
| 10 | STATE STREET CORP | 4,708,419 | $39.9M |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 4,529,185 | $38.4M |
| 12 | Logos Global Management LP | 3,850,000 | $32.6M |
| 13 | Octagon Capital Advisors LP | 3,166,600 | $26.8M |
| 14 | Balyasny Asset Management L.P. | 2,692,622 | $22.8M |
| 15 | Commodore Capital LP | 2,575,000 | $21.8M |